be it as it may, I am still holding and buying. Intiger have a...

First 394 Last

Share
Profile

Follow
Chev007

260 Posts.

3

02/08/17

22:16

Post #: 26252889
Share

Originally posted by webbj ↑

The flip side would be sell into exhuberance.

One wonders if that's exactly what's happened and the smarties have left (or are leaving) the party and no longer participating in the commiserations.

Either some of the most vocal supporters have had a change of heart and the 'cheap' shares' are now too cheap, or perhaps penning a new summary thread to help newbie IAM investors understand what a bargain they are missing out on?

There is not much unique about what's happened here, some will come away shell shocked, convinced the system is rigged and possibly never try for a punt in the spec end of the market again.

Otherwise will always love a punt, keep chasing the dream and probably keep seeing the same outcome.

And the luckiest few will look back, see what was said, when, what the market reaction was and dissect exactly what transpired. For those few, they may do very well indeed.. seeing the same thing play out elsewhere and use their newfound observation to their advantage.

Ultimately though, the moral of the story would seem to be, school holidays really are problematic and if you are trying to outsource things to the phillipines be sure to check the dates and make sure they don't overlap with your asx reporting obligations.

Expand

be it as it may, I am still holding and buying. Intiger have a product/service that is proven successful. It is generating income and now they are positioning themselves to promote.

IAM Price at posting: 2.2¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 47 more messages in this thread...

First 394 Last

Add CF1 (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $12.58M

Open	High	Low	Value	Volume
2.2¢	2.2¢	2.2¢	$2	91

Buyers (Bids)

No.	Vol.	Price($)
1	491617	2.0¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	1916	3

View Market Depth

No.	Vol.	Price($)
1	491617	0.020
1	200000	0.019
3	1434231	0.018
1	1000000	0.017
1	1000000	0.016

Price($)	Vol.	No.
0.022	1916	3
0.023	470043	2
0.024	125000	1
0.026	64744	1
0.028	483161	1

Last trade - 13.05pm 07/10/2024 (20 minute delay)

CF1 (ASX) Chart

be it as it may, I am still holding and buying. Intiger have a...

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

be it as it may, I am still holding and buying. Intiger have a...

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News